Guidance for including elderly patients in clinical trials
Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines guidance for including older adults in clinical trials.
Read on for session two: key design considerations when including elderly patients in clinical trials, with a focus on cognitive assessment.
Why are elderly patients under-represented in clinical trials?
Older adults are consistently under-represented in clinical trials, even though they take more prescription medications than any other group. In this two part series, Dr Kiri Granger will explore this under-presentation and outline practical considerations for including older adults in clinical trials.
Read on for session one: the importance of addressing the evidence-practice gap.
Assessment of cognitive safety in clinical drug development
Published in Drug Discovery Today, our keynote review outlines the rationale, study design, and methods for cognitive safety assessment during clinical drug development.